CN115190884B - 新型细胞递送方法 - Google Patents

新型细胞递送方法

Info

Publication number
CN115190884B
CN115190884B CN202080093916.XA CN202080093916A CN115190884B CN 115190884 B CN115190884 B CN 115190884B CN 202080093916 A CN202080093916 A CN 202080093916A CN 115190884 B CN115190884 B CN 115190884B
Authority
CN
China
Prior art keywords
cpp
peptide
seq
cell
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080093916.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN115190884A (zh
Inventor
沙恩·斯通
克林顿·哈尔
安雅·施蒂恩魏斯
保拉·坎宁安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pyc Therapeutics Ltd
Original Assignee
Pyc Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904882A external-priority patent/AU2019904882A0/en
Application filed by Pyc Therapeutics Ltd filed Critical Pyc Therapeutics Ltd
Publication of CN115190884A publication Critical patent/CN115190884A/zh
Application granted granted Critical
Publication of CN115190884B publication Critical patent/CN115190884B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
CN202080093916.XA 2019-12-20 2020-12-18 新型细胞递送方法 Active CN115190884B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904882 2019-12-20
AU2019904882A AU2019904882A0 (en) 2019-12-20 Novel Cellular Delivery Methods
PCT/AU2020/051397 WO2021119756A1 (en) 2019-12-20 2020-12-18 Novel cellular delivery methods

Publications (2)

Publication Number Publication Date
CN115190884A CN115190884A (zh) 2022-10-14
CN115190884B true CN115190884B (zh) 2026-01-13

Family

ID=76476454

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080093916.XA Active CN115190884B (zh) 2019-12-20 2020-12-18 新型细胞递送方法

Country Status (10)

Country Link
US (1) US20230048338A1 (OSRAM)
EP (1) EP4077354A4 (OSRAM)
JP (1) JP7684971B2 (OSRAM)
KR (1) KR20220117914A (OSRAM)
CN (1) CN115190884B (OSRAM)
AU (1) AU2020406670B2 (OSRAM)
BR (1) BR112022012057A2 (OSRAM)
CA (1) CA3161901A1 (OSRAM)
IL (1) IL294050A (OSRAM)
WO (1) WO2021119756A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022022889A2 (pt) 2020-05-11 2023-04-04 Stoke Therapeutics Inc Oligômeros antissentido de opa1 para tratamento de condições e doenças
US20250114464A1 (en) * 2022-01-27 2025-04-10 The Governors Of The University Of Alberta Pre-mrna slice modulating peptide-conjugated antisense therapeutics for the treatment of diseases
WO2024073042A1 (en) * 2022-09-30 2024-04-04 Entrada Therapeutics, Inc. Ocular delivery of therapeutic agents
WO2024254639A1 (en) * 2023-06-16 2024-12-19 PYC Therapeutics Limited Compositions and methods for treatment of kidney disease
WO2025238644A1 (en) * 2024-05-16 2025-11-20 Skip Therapeutics Ltd. Compositions and methods for treating retinal diseases
WO2025240993A1 (en) * 2024-05-24 2025-11-27 PYC Therapeutics Limited Improved cell penetrating peptides and related compositions and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103096932A (zh) * 2010-06-14 2013-05-08 弗·哈夫曼-拉罗切有限公司 细胞穿透肽及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520803A (ja) * 2000-04-21 2004-07-15 コリクサ コーポレイション 尋常性挫瘡の治療および診断のための組成物および方法
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20060107345A1 (en) * 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
PL2707014T3 (pl) 2011-05-13 2015-12-31 Koebenhavns Univ University Of Copenhagen Dimeryczne inhibitory PSD-95 o wysokim powinowactwie i ich zastosowanie w terapii niedokrwiennego uszkodzenia mózgu oraz leczeniu bólu
US10316061B2 (en) 2014-10-02 2019-06-11 Temple University Of The Commonwealth System Of Higher Education Synthesis of cell penetrating peptides for drug delivery and stem cell applications
CN110996970A (zh) * 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
US20210087238A1 (en) 2017-07-28 2021-03-25 Phylogica Limited Cell penetrating peptides and related compositions and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103096932A (zh) * 2010-06-14 2013-05-08 弗·哈夫曼-拉罗切有限公司 细胞穿透肽及其用途

Also Published As

Publication number Publication date
IL294050A (en) 2022-08-01
BR112022012057A2 (pt) 2022-08-30
AU2020406670B2 (en) 2026-03-05
JP2023511501A (ja) 2023-03-20
EP4077354A1 (en) 2022-10-26
CA3161901A1 (en) 2021-06-24
JP7684971B2 (ja) 2025-05-28
EP4077354A4 (en) 2024-01-24
AU2020406670A1 (en) 2022-07-14
WO2021119756A1 (en) 2021-06-24
CN115190884A (zh) 2022-10-14
KR20220117914A (ko) 2022-08-24
US20230048338A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
AU2020406670B2 (en) Novel cellular delivery methods
CA2800650C (en) Cell-penetrating peptides and uses therof
US20210087238A1 (en) Cell penetrating peptides and related compositions and methods
Zorko et al. Studies of cell-penetrating peptides by biophysical methods
CN105659088A (zh) 用于监测肽的细胞运输的方法
US20230241234A1 (en) Cell membrane penetrating conjugates
CN113966233A (zh) 用于基因编辑的细胞膜穿透缀合物
RU2842811C1 (ru) Новые способы доставки в клетку
Nanda et al. 4 (R/S)-Guanidinylprolyl collagen peptides: on-resin synthesis, complexation with plasmid DNA, and the role of peptides in enhancement of transfection
EP4079845A1 (en) Method for enhancing water solubility of target protein by whep domain fusion
KR20090122769A (ko) 세포내로 단백질을 전달하는 방법 및 이를 위한 펩타이드
EP2668276A2 (en) Enhanced protein transduction
Wen Development and Application of Cell Penetrating Beta-Hairpin and Alpha-Helical Peptides
Bhosle Arginine-rich tat-and (RXR)-motif peptidomimetics for DNA/RNA binding, antimicrobial action and cell penetration
Nore A synthetic cell-penetrating peptide (CPP) with protamine conjugate utilized for gene delivery
HK1180232B (en) Cell-penetrating peptides and uses thereof
Mussbach et al. Transduction of peptides, proteins and nucleotides into live cells by cell penetrating peptides
HK1180232A (en) Cell-penetrating peptides and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant